Department of Medicine, University of Toronto, Ontario, Canada.
Am J Med. 2012 Oct;125(10):956-62. doi: 10.1016/j.amjmed.2012.03.015. Epub 2012 Jul 25.
The inflammatory state of atherosclerosis has been established as those with chronic inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematosus, who are at increased risk of coronary artery disease. A systematic search was conducted to retrieve high-quality, peer-reviewed studies of inflammatory bowel disease and coronary artery disease. Recent literature supports an association between inflammatory bowel disease and coronary artery disease. While hypertension increases the risk of coronary artery disease in inflammatory bowel disease patients, other typical risk factors have not been confirmed, and markers of inflammation may predict coronary artery disease risk in this population. Common cardiovascular drugs such as statins and angiotensin-converting enzyme inhibitors may have dual potential for controlling inflammatory bowel disease and preventing or treating coronary artery disease. Large, prospective, longitudinal studies can help to determine the true prevalence of coronary artery disease in this population and confirm risk factors. In the absence of such evidence, physicians should be cognizant of increased coronary artery disease risk in inflammatory bowel disease patients without traditional risk factors and consider primary preventive strategies.
动脉粥样硬化的炎症状态已被确定为那些患有慢性炎症性疾病的人，如类风湿关节炎和系统性红斑狼疮，他们患冠状动脉疾病的风险增加。进行了系统搜索，以检索高质量的、同行评议的炎症性肠病和冠状动脉疾病的研究。最近的文献支持炎症性肠病与冠状动脉疾病之间存在关联。虽然高血压会增加炎症性肠病患者患冠状动脉疾病的风险，但其他典型的风险因素尚未得到证实，炎症标志物可能可以预测该人群的冠状动脉疾病风险。他汀类药物和血管紧张素转换酶抑制剂等常见心血管药物可能具有控制炎症性肠病和预防或治疗冠状动脉疾病的双重潜力。大型前瞻性纵向研究可以帮助确定该人群中冠状动脉疾病的真实患病率，并确认风险因素。在缺乏这种证据的情况下，医生应该意识到没有传统风险因素的炎症性肠病患者的冠状动脉疾病风险增加，并考虑采取主要预防策略。
